Trovagene Inc. (NASDAQ: TROV) develops diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company’s urine-based testing platform helps to enhance cancer care management and women’s healthcare. The company’s technology is also applied in various testing, including tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. For more information, visit the company’s website at www.trovagene.com.